NCT02336087View on ClinicalTrials.gov

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 14, 2016

Primary Completion Date

October 4, 2020

Study Completion Date

January 9, 2026

Conditions
Pancreatic AdenocarcinomaUnresectable Pancreatic CarcinomaStage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

DRUG

Metformin Hydrochloride

Given PO

DIETARY_SUPPLEMENT

Therapeutic Dietary Intervention

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (4)

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

91790

City of Hope West Covina, West Covina

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER